Nigerian Researcher Exposes HIV Protein Behind Memory Loss, Brain Damage

A Nigerian scholar, Elizabeth Oladipo, has received international recognition after presenting groundbreaking research on how HIV affects the brain at the prestigious University of Nebraska Medical Center (UNMC), Omaha, USA.

Her study revealed that the HIV Tat protein — a molecule that remains active in the brain even when patients are on combined antiretroviral therapy (cART) — contributes to long-term neurological damage, including memory loss, poor cognition, and neurodegeneration.

Experts say her findings could help shape new strategies to reduce the hidden impact of HIV on the brain and improve long-term quality of life for millions of patients worldwide.

Globally, more than 39 million people live with HIV, with Nigeria carrying one of the heaviest burdens.

Speaking with journalists during a poster presentation, Oladipo explained that while antiretroviral therapy has transformed HIV into a manageable condition, Tat remains a persistent threat.

“Tat persists in the brain long after the virus has been suppressed in the blood, which makes it particularly dangerous. My research is focused on understanding how Tat interacts with brain cells so we can develop ways to protect patients from long-term neurological complications,” she said.

Her work has drawn strong praise from fellow researchers and senior scientists, who commended both the robustness of her data and the clarity of her presentation. Many described her study as a potential breakthrough in addressing HIV-associated neurocognitive disorders, which remain a challenge despite advances in treatment.

Oladipo, who has dedicated her career to advancing human health through science, expressed optimism that her findings would strengthen global efforts against HIV.